European Primary Care Cardiovascular Society

Statins are underutilized in peripheral artery disease patients

Apr. 10, 2018 - Arya S et al. - Circulation. 2018

In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

Slides | Lipid-lowering: the evidence, the guidelines, the clinical reality

Mar. 15, 2018 - Barcelona, Spain - Prof. Frank Visseren - Utrecht, The Netherlands
**EPCCS 2018** Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.

EPCCS 2018 Slides prepared and presented byProf. Frank Visseren (Utrecht, The Netherlands), here offered as an educational service.

Managing elevated lipids and statins – the good, the bad and the ugly?

Prof. Frank Visseren - UMC Utrecht, The Netherlands

EPCCS 2018 An impression of the presentation of Prof. Frank Visseren on the evidence, the guidelines and the clinical reality of lipid-lowering therapies, given during the Annual EPCCS CV Summit.

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France
Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater in patients who had a higher LDL-c at baseline.

Shift of statin eligibility to more subjects at intermediate CV risk with new criteria

Mar. 21, 2018 - Cesena FHY, et al. - Am J Cardiol 2018

Defining statin eligibility based on the predicted CV benefit, rather than the absolute CV risk, shifts statin eligibility to more intermediate CV risk subjects.

MACE safely reduced by another PCSK9 inhibitor in long term outcomes trial in high-risk patients

Presented at ACC.18 by Ph. Gabriel Steg (Paris, France)

Mar. 13, 2018 - news

ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.

Children with a higher BMI have an increased risk of cardio-metabolic disease later in life

Mar. 1, 2018 - Geng T, et al. - Diabetes Care 2018

A genetic predisposition to higher childhood BMI was associated with an increased risk of type 2 diabetes, coronary artery disease, and cardio-metabolic traits in adult life.

Disinformation provided by the anti-statin lobby should be fiercely counteracted to protect patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

New method works better than Friedewald formula to calculate LDL-c, also in non-fasting samples

Jan. 4, 2018

The method is an adaptation of the Friedwald formula that incorporates a patient-specific TG:VLDL-ratio. Added accuracy is largest in those with LDL-c <70 mg/dL, without added expense.

ESC/EAS statin eligibility in primary prevention may be expanded to high TG levels

Nov. 29, 2017 - Madsen CM et al., Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

Lower risk of Parkinson’s Disease seen with statin therapy

Nov. 27, 2017 - Poly TN et al., Neuroepidemiology 2017

In a meta-analysis of 13 observational studies, statin use was associated with a modest reduction in the risk of developing Parkinson’s Disease compared with not using statins.